Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles (2023 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Amortizatization of Intangibles of $17000.0 for Q1 2026, down 94.16% year-over-year from $291000.0 in Q1 2025, and down 93.49% quarter-over-quarter from $261000.0 in Q4 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $17000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 94.16% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 16.39% YoY), while the FY2025 annual figure was $1.3 million, up 17.88% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $17000.0, down from $261000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $524000.0 in Q3 2024, with the low at $17000.0 in Q1 2026.
- The 4-year median for Amortizatization of Intangibles is $258000.0 (2023), against an average of $261307.7.
- The sharpest annual moves came in 2024 and 2026: Amortizatization of Intangibles surged 113.88% in 2024, then slumped 94.16% in 2026.
- Corvus Pharmaceuticals' Amortizatization of Intangibles stood at $127000.0 in 2023, then surged by 90.55% to $242000.0 in 2024, then rose by 7.85% to $261000.0 in 2025, then plunged by 93.49% to $17000.0 in 2026.
- Business Quant data shows CRVS's Amortizatization of Intangibles at $17000.0 in Q1 2026, $261000.0 in Q4 2025, and $459000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | -185,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -185,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 261,000.00 |
| Sep 30, 2025 | 459,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 291,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 524,000.00 |
| Jun 30, 2024 | 224,000.00 |
| Mar 31, 2024 | 151,000.00 |
| Dec 31, 2023 | 127,000.00 |
| Sep 30, 2023 | 245,000.00 |
| Jun 30, 2023 | 258,000.00 |
| Mar 31, 2023 | 264,000.00 |